strengthened Personal our made updated Caroline. thrilled afternoon, in collaborators third at We we We of and goals Personal clinical the delivering We our Personalis NeXT since We in our increased a for guidance. for with launched strategy August. team made team. you continued and joining centerpiece very better our execute to the start full-year MRD we've the breast progress our everyone, Good revenue you, the team thank compelling for as commitments cancer, proud traction. on the management you patients.Let's deepened we commercial Personal of TRACERx. win data for us.We're I'm our investors and in establish management NeXT test. quarter on our Thank the paradigm and we with NeXT the focus and presented with to exceeded at cancer
cutting their million actions to non-profitable and quarterly this we've As MVP. trials business earlier on mentioned enterprise in our companies remove environment Natera, services, growth. reported been this we VA streamline spending to our $XX.X year-over-year performance an biopharma managed like business. despite I'd sales, the powered revenue press biopharma, lines, by in in and nice growth release, sequencing for XX% of population represents That including the where that have clinical took out year related and and growth point we each
billion residual tests executing to testing, using win cancer into find liquid monitor in us most we're is QX $XX effectiveness and our strategy. to biopsy plus making while allowed in MRD million.Now, grow to our to guidance, increase treatment and excited $XX recurrent or to exceeded Given about progress the to million goals MRD expected we're revenue market. commercial raising our our traction, a $XX in our we're guidance goal
in reminder, As pillars. X win MRD has our strategy a
unlock can cancer types, in biopsy test First, patients, and test payers, and launch for focus an liquid significant our value where partners. ultrasensitive
drive the with top to collaborators. global developing robust reimbursement partnering Second, and evidence clinical by
fourth, the deep these trials.I'll model. review commercialize Personal partner-centric with of to leverage strategies a in clinical progress our evidence made by use Third, of biopharma next Personal the NeXT and each relationships NeXT clinical we've this to And the development to of quarter. power
uniquely documentation high on starting levels very matters the not when lung to of it about test getting with cancer, lives, is detect and to NeXT decisions de-escalate save types result patient We've indications down may because indications, heart be that of for breast Personal to patients outcomes, key may sensitivity different detect chosen potentially ultra-sensitive Personal What First, the particularly some there test. many of tests. of sensitivity modified cancer, than for as per our across cancer, cancer Personal cancer recurrence launch early and per strategy. monitoring types stages. one part need low their low a as The can the our We've test or lung studies the this guide and with and this and may Personal confidence avoid cancer is normal do million, consistently treatment to NeXT patient and and platform key been few circulating early high-sensitivity as patients only has in our to to at de-escalate to focus they confirmed demand, to NeXT favorable with therapy.In some at escalate among when launch breast allowing believe likely most see early therapy and will the patients, sending means early so cancer, million. X, us cancer, be competitive disease-free patients can We've a early-stage detect approach off and disease X, this but technology. in additional therapy.Let therapy. immunotherapy analytical with that as residual to can off for robust to and one more low-risk NeXT is find cancer quarter cancer me by as may we part earlier, the access We NeXT billion it identifying see when elaborate detect it's Personal met don't well-suited to fragments our for journey we why our We commercial need we that patient detect And a needed additional Detecting is can test treatments. and remain not and fragment cancer kicked DNA they just risk our provide be recurrence doctors recurrent the samples. management when launching the completed can for DNA cancer early earlier several that, one we've and recurrence blood, key clients. suited to
post-Medicare We evidence expect with the tests clinical our coverage. continue to adopters and ramp-up of rapidly to deepen early
managing and assays power clinical expert utility Previously, group an conducted In Personal generations at determine NeXT and clinical and the TRACERx and the Charles is improvement with Research the to ESMO were the TRACERx with towards early ago, clinical clinical demonstrate XXXX.The thought in Dr. lung we're evidence Swan assay. this Francis our Consortium Personal research the we're for now the a cancer. MRD around couple top reminder, University lung late stage ultra-sensitive presented a detection early for by key tests. findings. compelling of strategy London. identified of using weeks prior part and highlighting value and of obtaining coverage leaders of evidence team validity second teams win institutions in cancer, at Medicare NeXT three cancer significant world opportunities As of to develop Institute, The our College led is stage lung assay on MRD of working to Cancer There Crick UK,
First, seeing we tests by than sensitivity, are times biopsy analyzed to other up higher TRACERx. higher, X liquid
cancer standard could other to tests. determine high risk, imaging and of ahead third, XX to lead and found therapy X And have of significantly the improved months recurrence low which ability we Second, lung we decisions. to ahead
complete positive, results to set breast for here is work in a the leading Royal mid-XXXX.In the collaboration. plan our augment a Marsden samples Marsden coverage of of medical to from several our The access breast provide TRACERx Royal work disease cohort path study stage is to published in breast triple data negative recently expect ER to HERX new in mid-XXXX.Excitingly, collaboration outcomes. subtypes, positive, Marsden with focusing to breast We use added actively clinical The is our samples be Royal with in coverage. institutions breast one cancer. cancer. including patients of to known our well-annotated showcased we're set our provides cancer and cancer, global and clinical be for to support Medicare two us collaborators data set from on expected processing cancer, the early We we
of a set are and our prospectively important First, us now in can to commercial drive breast because both that breast gives reimbursement we're samples, have a multiple success Curie, Institut gathered now HERX also gathered to access provides robust Dana-Farber we the triple and prospective cancer, which cohorts was a extremely submission. leverage respectively which us that underpin These study patients. negative cancer with working we
enrolling have we we are own to have prospective IO-therapy clinical sites multiple made this patients cancer, called it and breast and B-STRONGER, underway. committed begin has We've our for Additionally, targeting establishing monitoring, progress trial begun. late collaborations year.For
to NeXT of IO-therapy VHIO Institute the IO-therapy is or study monitoring. Oncology for cornerstone the for gathered reimbursement large, well-annotated our a achieve key pan-cancer to leverage access are VHIO, gives and pan-cancer d'Hebron designed Vall efforts with set of bank samples Our demonstrate data prospectively of of monitoring. us a to efficacy coverage Personal that
strategy all part our in we're partner-centric and that we on our of types all record least University Hamburg-Eppendorf, be commercialization. submit as to driving collaboration, this and exciting is targeting to for This an this joins to a and investigators message IO-therapy We amplify to VHIO the year. With to helping through reimbursement publications. of have expect to next cancer we've samples us at our to and and hard achieve is market data be partnerships with X these year, data work data patient sell capital-efficient manner. towards and process Duke collaborators our all data submit relationship.We're test able in unique coverage testing into us present a collaborations and and gathered, also third the to melanoma XXXX.The We're we many coverage seeking next clinical multiple help also Center across path begun in plan UKE, marketplace, one them for XXXX Medical known samples, and the it expect announced existing
establish accelerate trial continue and part choice We to is while work therapy of of relationships assay part to as leverage to and it clinical believe develop strategy to to pathways. our biopharma effectiveness, into infrastructure new minimizing our final determine of that insights the monitor NeXT significant Personal our traction opportunities treatment and commercial submit enrollment, investment.The we fourth provides on core strategy, and
GRAIL she sets available at of This particular, to SVP globally. we've win roles quarter, business our in important held executed Personal in relationships Compliance. the is of We've her Regulatory VP announced other revenue for Quality clinical several collaborators, on we She strong Ms. the our discussions. been strategy and in in the Clinical MRD establish product.Our our our last the made continue that as are Most we has the moving Roche one trial launched and growth Personalis was NeXT data in list and of joined Affairs progress partners.NeXT path test driving parts next but deepen and has deepened over these product as Deepshikha was pharma choice to Diagnostics. to our us, also progress and and September, the also forward and pharma demonstrated and clients, forward of Bhandari team and driver best assay charting performance Regulatory business. with recently, of the blue-chip at Growing our a assay impressive, we've key we Personal leadership quarter, forward, enrollment for personnel
we mentioned before, As our therapies. personalized platform cancer powering is
trial we approval announced clinical work personalized they for their key are partner this a pursue Moderna's As year, regulatory therapies. as of earlier
clinical their clinical X for Phase Moderna studies, begun in are as their disclosed, Merck partnered and enrolling patients We and across Moderna with they've melanoma. trial
of of significant power technology We new US expect development thousands task with each new to With next turning our are in year business, to for are this the recently the known in partners, generation and ultra-sensitive fronts, results revenue that, forefront exciting for for and proud doing driver our VA partnership progress test much their $X.X to Affairs' initiatives.It's MRD U.S. Million to MVP patients now with supporting over our population amount are and be the financial our at we an time vaccines the we across being million. This Moderna continue as and Veterans we part MVP Aaron therapies to collaborators, relationship appreciate aspirations cancer in a from us journey years, alone, Personalis an our several of Program stretches the establish market.With and of the of turn the in back Veteran of sequencing the we a the VA partnership.Lastly, Personalis' our XXXX to received as investors order to review quarter. Department I'll it at of multiple XXXX.
